Biogen Idec Inc, Genentech Inc, Roche Holding AG and Chugai Pharmaceutical Co 
Ltd are developing ocrelizumab, a humanized mAb against CD20, for the potential 
treatment of inflammatory disorders and B-cell malignancies. Ocrelizumab is 
undergoing phase III clinical trials for rheumatoid arthritis and lupus 
nephritis, and phase II trials for multiple sclerosis and hematological cancer. 
Previously, ocrelizumab was also being developed for the treatment of systemic 
lupus erythematosus (SLE) and neuromyelitis optica; however, development for SLE 
has been discontinued. No development has been reported for neuromyelitis optica 
and as of January 2007, this indication had been removed from the company 
pipeline.